Company News
-
Feb 23, 2021Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing
-
Feb 1, 2021Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
-
Feb 1, 2021Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
-
Dec 4, 2020Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates
-
Nov 3, 2020CEPI extends partnership with Clover Biopharmaceuticals to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure
-
Sep 25, 2020Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program
-
Sep 25, 2020Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate
-
Jul 8, 2020CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate
-
Jun 19, 2020Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate
-
Jun 8, 2020GL Ventures Completes $24 Million Series B-2 Investment in Clover Biopharmaceuticals
-
Apr 27, 2020CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals’ Australian Subsidiary
-
Mar 24, 2020Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
-
Feb 24, 2020Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System
-
Feb 10, 2020Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients
-
Jan 28, 2020Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Coronavirus (2019-nCoV)
-
Jan 10, 2020Clover Doses First Patient in Phase I Study of SCB-313 in China for Malignant Pleural Effusions (MPE)
-
Dec 30, 2019Clover Initiates Phase III Study of Etanercept Biosimilar Candidate SCB-808 in China
-
Nov 28, 2019Clover Completes $43 Million Series B Financing
-
Nov 21, 2019Clover Doses First Patient in Phase I Study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)
-
Sep 29, 2019Clover Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites